obesity treatment with bariatric surgery vs glp-1 receptor agonists Metabolic vs. for Management GLP-1 shots vs bariatric surgery.

Xu et al., 2017)

Hui H, Farilla L, Merkel P, Perfetti R (2002) The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects

The goal is to get the peptide as close to the target tissue as possible, since BPC-157 acts primarily locally

Are There Specific Patient Populations Who Might Benefit Most from GLP-Agonists

Clinical assessment includes diagnostic imaging, serum testing, possible biopsy analysis and consultation with a nephrologist to reduce the risk for irreversible damage to the renal system and to rule out other potential causes of kidney injury

HPLC analysis liquid chromatography is the gold standard